IFN-α is a cytokine that in the past has been used to treat several cancers, such as multiple myeloma, chronic myelogenous leukemia (CML), malignant melanoma and renal cancer (8) but in general with a low-rate of success except partly for CML (9). This evidence concerns the gene IFNA17 and chronic myelogenous leukemia, BCR-ABL1 positive.